vs
Side-by-side financial comparison of Lovesac Co (LOVE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $150.2M, roughly 1.3× Lovesac Co). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs 0.2%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-10.2M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -22.6%).
The Lovesac Company is an American furniture retailer, specializing in a patented modular furniture system called Sactionals. Sactionals consist of two combinable pieces, “Seats” and “Sides,” as well as custom-fit covers and associated accessories. Lovesac also sells Sacs, a bag seat filled with a proprietary foam mixture.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LOVE vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $150.2M | $196.9M |
| Net Profit | $-10.6M | — |
| Gross Margin | 56.1% | 79.5% |
| Operating Margin | -10.5% | 1.2% |
| Net Margin | -7.0% | — |
| Revenue YoY | 0.2% | 5.1% |
| Net Profit YoY | -114.0% | — |
| EPS (diluted) | $-0.72 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $150.2M | $196.9M | ||
| Q3 25 | $160.5M | $179.5M | ||
| Q2 25 | $138.4M | $181.1M | ||
| Q1 25 | $241.5M | $168.9M | ||
| Q4 24 | $149.9M | $187.3M | ||
| Q3 24 | $156.6M | $168.6M | ||
| Q2 24 | $132.6M | $178.0M | ||
| Q1 24 | $250.5M | $167.1M |
| Q4 25 | $-10.6M | — | ||
| Q3 25 | $-6.7M | $5.4M | ||
| Q2 25 | $-10.8M | $-4.8M | ||
| Q1 25 | $35.3M | $4.8M | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-5.9M | $-143.5M | ||
| Q2 24 | $-13.0M | $18.9M | ||
| Q1 24 | $31.0M | $9.0M |
| Q4 25 | 56.1% | 79.5% | ||
| Q3 25 | 56.4% | 80.9% | ||
| Q2 25 | 53.7% | 77.4% | ||
| Q1 25 | 60.4% | 79.7% | ||
| Q4 24 | 58.5% | 78.7% | ||
| Q3 24 | 59.0% | 76.9% | ||
| Q2 24 | 54.3% | 75.1% | ||
| Q1 24 | 59.7% | 71.6% |
| Q4 25 | -10.5% | 1.2% | ||
| Q3 25 | -5.5% | 3.5% | ||
| Q2 25 | -10.8% | 4.7% | ||
| Q1 25 | 19.7% | 1.2% | ||
| Q4 24 | -5.2% | 13.2% | ||
| Q3 24 | -5.3% | -82.8% | ||
| Q2 24 | -13.5% | 15.9% | ||
| Q1 24 | 16.1% | 7.9% |
| Q4 25 | -7.0% | — | ||
| Q3 25 | -4.1% | 3.0% | ||
| Q2 25 | -7.8% | -2.7% | ||
| Q1 25 | 14.6% | 2.8% | ||
| Q4 24 | -3.3% | — | ||
| Q3 24 | -3.7% | -85.1% | ||
| Q2 24 | -9.8% | 10.6% | ||
| Q1 24 | 12.4% | 5.4% |
| Q4 25 | $-0.72 | $0.05 | ||
| Q3 25 | $-0.45 | $0.12 | ||
| Q2 25 | $-0.73 | $-0.11 | ||
| Q1 25 | $2.22 | $0.10 | ||
| Q4 24 | $-0.32 | $0.38 | ||
| Q3 24 | $-0.38 | $-3.11 | ||
| Q2 24 | $-0.83 | $0.39 | ||
| Q1 24 | $1.91 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.7M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $189.3M | $693.1M |
| Total Assets | $495.5M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.7M | $238.4M | ||
| Q3 25 | $34.2M | $246.3M | ||
| Q2 25 | $26.9M | $445.9M | ||
| Q1 25 | $83.7M | $493.6M | ||
| Q4 24 | $61.7M | $484.6M | ||
| Q3 24 | $72.1M | $453.8M | ||
| Q2 24 | $72.4M | $404.2M | ||
| Q1 24 | $87.0M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $189.3M | $693.1M | ||
| Q3 25 | $197.5M | $727.2M | ||
| Q2 25 | $201.2M | $757.8M | ||
| Q1 25 | $216.4M | $798.5M | ||
| Q4 24 | $196.5M | $778.3M | ||
| Q3 24 | $202.1M | $749.6M | ||
| Q2 24 | $205.3M | $879.3M | ||
| Q1 24 | $217.5M | $892.2M |
| Q4 25 | $495.5M | $1.3B | ||
| Q3 25 | $493.7M | $1.3B | ||
| Q2 25 | $483.7M | $1.5B | ||
| Q1 25 | $532.3M | $1.6B | ||
| Q4 24 | $499.7M | $1.6B | ||
| Q3 24 | $481.1M | $1.5B | ||
| Q2 24 | $477.2M | $1.6B | ||
| Q1 24 | $482.2M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.9M | $43.7M |
| Free Cash FlowOCF − Capex | $-10.2M | $43.5M |
| FCF MarginFCF / Revenue | -6.8% | 22.1% |
| Capex IntensityCapex / Revenue | 3.5% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.9M | $43.7M | ||
| Q3 25 | $12.2M | $60.8M | ||
| Q2 25 | $-41.4M | $12.0M | ||
| Q1 25 | $44.0M | $35.5M | ||
| Q4 24 | $-4.2M | $33.1M | ||
| Q3 24 | $6.2M | $53.9M | ||
| Q2 24 | $-7.0M | $53.2M | ||
| Q1 24 | $56.3M | $49.1M |
| Q4 25 | $-10.2M | $43.5M | ||
| Q3 25 | $7.8M | $57.0M | ||
| Q2 25 | $-50.0M | $9.3M | ||
| Q1 25 | $38.7M | $26.9M | ||
| Q4 24 | $-6.6M | $31.0M | ||
| Q3 24 | $119.0K | $49.8M | ||
| Q2 24 | $-14.3M | $51.6M | ||
| Q1 24 | $49.5M | $46.3M |
| Q4 25 | -6.8% | 22.1% | ||
| Q3 25 | 4.9% | 31.7% | ||
| Q2 25 | -36.1% | 5.1% | ||
| Q1 25 | 16.0% | 15.9% | ||
| Q4 24 | -4.4% | 16.6% | ||
| Q3 24 | 0.1% | 29.6% | ||
| Q2 24 | -10.8% | 29.0% | ||
| Q1 24 | 19.8% | 27.7% |
| Q4 25 | 3.5% | 0.1% | ||
| Q3 25 | 2.7% | 2.2% | ||
| Q2 25 | 6.2% | 1.5% | ||
| Q1 25 | 2.2% | 5.1% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 3.9% | 2.4% | ||
| Q2 24 | 5.5% | 0.9% | ||
| Q1 24 | 2.7% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.25× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | 1.82× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOVE
| Showrooms | $102.7M | 68% |
| Internet | $37.3M | 25% |
| Other | $10.2M | 7% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
